LIXTE BIOTECHNOLOGY HOLDINGS INC C/WTS 30/11/2025 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.33.

EBIT: As of FY2025 Q3, the actual value is USD -1.805 M.

Operational Metrics

• Net Loss: The company reported a net loss of $1,980,398 for the three months ended September 30, 2025, compared to $986,030 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $3,465,626, compared to $2,968,271 in 2024.
• Research and Development Costs: For the three months ended September 30, 2025, research and development costs were $50,696, a decrease from $361,630 in 2024. For the nine months ended September 30, 2025, these costs were $202,801, down from $691,402 in 2024.
• General and Administrative Costs: For the three months ended September 30, 2025, general and administrative costs were $1,750,658, up from $621,627 in 2024. For the nine months ended September 30, 2025, these costs were $3,080,302, compared to $2,267,890 in 2024.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was $1,982,720 for the nine months ended September 30, 2025, compared to $2,565,861 in 2024.
• Investing Cash Flow: Net cash used in investing activities was $2,637,360 for the nine months ended September 30, 2025, primarily for the purchase of digital assets.
• Financing Cash Flow: Net cash provided by financing activities was $6,469,002 for the nine months ended September 30, 2025, primarily from the sale of securities.

Unique Metrics

• Digital Assets: The company recorded an unrealized net loss from a decrease in the fair value of digital assets of $182,887 for the three months ended September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company is focusing on advancing LB-100 in high-need cancer indications and pursuing acquisitions of complementary oncology assets to enhance its pipeline, accelerate development, and create durable value for patients and shareholders.
• Non-Core Business: The company is in advanced negotiations regarding potential transactions consistent with its strategy, although there can be no assurance that any transaction will be completed.

Priority

• The company estimates that its existing cash resources at September 30, 2025, will provide sufficient working capital to fund its operations as currently configured, including its ongoing clinical trial program, for at least the next 12 months.